Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 7/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 7/20 | 0.46 |
| ▸ | PFKFB4 | Q16877 | 7/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669992 | 1.00 | NPSR1 (0.48) | NPSR1L3MBTL1CMA1PFKFB3PFKFB4 | |
| SCHEMBL5669995 | 1.00 | NPSR1 (0.48) | NPSR1L3MBTL1CMA1PFKFB3PFKFB4 | |
| SCHEMBL13508287 | 0.81 | NPSR1 (0.56) | NPSR1L3MBTL1CMA1PFKFB3PFKFB4 | |
| SCHEMBL13508316 | 0.79 | NPSR1 (0.60) | NPSR1L3MBTL1CMA1PFKFB3PFKFB4 | |
| SCHEMBL5669997 | 0.78 | NPSR1 (0.41) | NPSR1L3MBTL1CMA1PFKFB3PFKFB4 | |
| SCHEMBL2899531 | 0.78 | NPSR1 (0.41) | NPSR1L3MBTL1CMA1PFKFB3PFKFB4 | |
| SCHEMBL2888157 | 0.76 | PSEN1 (0.68) | HTR6 | |
| SCHEMBL2888245 | 0.76 | PSEN1 (0.68) | HTR6 | |
| SCHEMBL2888247 | 0.76 | PSEN1 (0.68) | HTR6 | |
| SCHEMBL2888161 | 0.76 | PSEN1 (0.68) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227667-A1 | FLUORO- AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF | WYETH (US) | 2009-09-10 | — | — | US | claimed |
| US-7547725-B2 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2009-06-16 | — | — | US | claimed |
| US-20070254929-A1 | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2007-11-01 | — | — | US | claimed |
| US-7858658-B2 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090227667-A1 | FLUORO- AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7547725-B2 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2009-06-16 | — | — | US | disclosed |
| US-20070254929-A1 | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254929-A1 | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | SCN8A, CHD8, CHRNA7 | NPSR1 46/4885L3MBTL1 1180/4885CMA1 2373/4885 |
| US-20090227667-A1 | FLUORO- AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF | SCN8A, CHD8, CDR2 | NPSR1 47/4885L3MBTL1 1199/4885CMA1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.